Evidence map›Paper›PMID 31653948›Full record

ArticleScientific reports2019

Comparing modes of delivery of a combination of ion channel inhibitors for limiting secondary degeneration following partial optic nerve transection.

Lillian M Toomey, Carole A Bartlett, Nikolas Gavriel, Terence McGonigle, Maimuna Majimbi, Gopana Gopalasingam, Jennifer Rodger, Melinda Fitzgerald

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lillian M ToomeyExperimental and Regenerative Neurosciences, School of Biological Sciences, The University of Western Australia, 35 Stirling Hwy, Perth, 6009, Western Australia, Australia.
Carole A BartlettExperimental and Regenerative Neurosciences, School of Biological Sciences, The University of Western Australia, 35 Stirling Hwy, Perth, 6009, Western Australia, Australia.
Nikolas GavrielExperimental and Regenerative Neurosciences, School of Biological Sciences, The University of Western Australia, 35 Stirling Hwy, Perth, 6009, Western Australia, Australia.
Terence McGonigleCurtin Health Innovation Research Institute, Curtin University, Sarich Neuroscience Research Institute Building, 8 Verdun St, Nedlands, 6009, Western Australia, Australia.
Maimuna MajimbiCurtin Health Innovation Research Institute, Curtin University, Sarich Neuroscience Research Institute Building, 8 Verdun St, Nedlands, 6009, Western Australia, Australia.
Gopana GopalasingamExperimental and Regenerative Neurosciences, School of Biological Sciences, The University of Western Australia, 35 Stirling Hwy, Perth, 6009, Western Australia, Australia.
Jennifer RodgerExperimental and Regenerative Neurosciences, School of Biological Sciences, The University of Western Australia, 35 Stirling Hwy, Perth, 6009, Western Australia, Australia.ORCID http://orcid.org/0000-0003-3413-4229
Melinda FitzgeraldExperimental and Regenerative Neurosciences, School of Biological Sciences, The University of Western Australia, 35 Stirling Hwy, Perth, 6009, Western Australia, Australia. lindy.fitzgerald@curtin.edu.au.ORCID http://orcid.org/0000-0002-4823-8179
The University of Western Australia · AUCurtin University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Injury to the central nervous system is exacerbated by secondary degeneration. Previous research has shown that a combination of orally and locally administered ion channel inhibitors following partial optic nerve injury protects the myelin sheath and preserves function in the ventral optic nerve, vulnerable to secondary degeneration. However, local administration is often not clinically appropriate. This study aimed to compare the efficacy of systemic and local delivery of the ion channel inhibitor combination of lomerizine, brilliant blue G (BBG) and YM872, which inhibits voltage-gated calcium channels, P2X

Indexed as

AnimalsCalcium Channel BlockersCalcium ChannelsDrug Therapy, CombinationFemaleImidazolesMyelin SheathNerve DegenerationOptic NerveOptic Nerve InjuriesPiperazinesQuinoxalinesRatsReceptors, AMPAReceptors, Purinergic P2X7Rosaniline DyesCalcium Channel BlockersCalcium Channelscoomassie Brilliant BlueImidazoleslomerizinePiperazinesQuinoxalinesReceptors, AMPAReceptors, Purinergic P2X7Rosaniline DyesYM 872

Identifiers

PMID31653948
PMCPMC6814709
OpenAlexW2982147093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.